Steven Grinspoon, MD, on Targeting Endocrine Pathways in NAFLD

In this podcast, Steven Grinspoon, MD, discusses his session on endocrine pathways and therapeutic options for patients with nonalcoholic fatty liver disease, which he presented at Harvard University’s 21st Annual Symposium on NAFLD. Read the transcription here.

For more coverage of the symposium, visit our resource center.

Additional Resources:

• The 21st Annual Harvard Nutrition and Obesity Symposium Nonalcoholic Fatty Liver Disease (NAFLD): Mechanisms and Novel Therapeutics live streaming event. Massachusetts General Hospital. June 30, 2020. Accessed July 10, 2020. https://healthcare.partners.org/streaming/Live/MGH/2020.06.30_NAFLD_Symposium.html
• Balbi A. Novel therapeutics emerge for treating NAFLD via endocrine pathways. Published online July 10, 2020. Gastroenterology Consultant. https://www.consultant360.com/exclusive/gastroenterology/nafld-symposium/novel-therapeutics-emerge-treating-nafld-endocrine

Steven Grinspoon, MD, is a professor of medicine, chief of the Metabolism Unit, and director of the Nutrition Obesity Research Center at Harvard Medical School in Cambridge, Massachusetts.